Nano Dimension signed a non‑binding term sheet to merge with Infinite Epigenetics in a proposed $890M stock deal that would pivot the Waltham company into AI‑powered health diagnostics. The combined firm would seek the Nasdaq ticker IEAI and access to more than $400M in cash at closing.